Actelion Ltd. (SIX:ATLN) last week said it plans to focus R&D on specialty products, including Orphan diseases, immunomodulators and antibiotics, and out-license what remains of its primary care portfolio. The biotech already has discontinued three Phase II or Phase III primary care programs in the